Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis

Phase 4

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Ixekizumab
Drug: Guselkumab
Drug: Placebo

First Posted Date: 2018-06-29

Last Posted Date: 2020-07-28

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1027

Registration Number: NCT03573323

Locations: 🇺🇸
Johnson Dermatology, Fort Smith, Arkansas, United States
🇺🇸
Arlington Research Center, Inc, Arlington, Texas, United States
🇺🇸
Dermatology Clinical Trials, Newport Beach, California, United States

and more 117 locations

A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Phase 2

Active, not recruiting

Conditions: Alopecia Areata

Interventions: Drug: Baricitinib
Drug: Placebo

First Posted Date: 2018-06-27

Last Posted Date: 2024-05-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 824

Registration Number: NCT03570749

Locations: 🇯🇵
Hamamatsu University School of Medicine University Hospital, Hamamatsu, Shizuoka, Japan
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Coastal Clinical Research, Inc, Mobile, Alabama, United States

and more 72 locations

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

Phase 3

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: Baricitinib

First Posted Date: 2018-06-18

Last Posted Date: 2022-11-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 374

Registration Number: NCT03559270

Locations: 🇺🇸
University of Utah MidValley Dematology, Murray, Utah, United States
🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇺🇸
Wallace Medical Group, Inc., Los Angeles, California, United States

and more 71 locations

A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine

Phase 3

Completed

Conditions: Migraine

Interventions: Drug: Placebo
Drug: Galcanezumab

First Posted Date: 2018-06-18

Last Posted Date: 2020-07-08

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 463

Registration Number: NCT03559257

Locations: 🇬🇧
Kings College Hospital, London, Greater London, United Kingdom
🇺🇸
Health Research of Hampton Roads Inc, Newport News, Virginia, United States
🇨🇿
Clintrial, s.r.o., Praha 10, Hl. M. Praha, Czechia

and more 66 locations

A Study of the Effect of a Disease-Specific Migraine Smart Phone Application (App) on Participant Care

Not Applicable

Completed

Conditions: Migraine

Interventions: Other: Migraine App

First Posted Date: 2018-06-15

Last Posted Date: 2020-07-22

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 120

Registration Number: NCT03559088

Locations: 🇺🇸
Shiland Family Fort Mill, Fort Mill, South Carolina, United States
🇺🇸
Charlotte Internal Medicine, Charlotte, North Carolina, United States
🇺🇸
Charlotte Medical Clinic, Charlotte, North Carolina, United States

and more 13 locations

A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)

Phase 3

Terminated

Conditions: Psoriasis

Interventions: Drug: Mirikizumab

First Posted Date: 2018-06-14

Last Posted Date: 2023-03-21

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1936

Registration Number: NCT03556202

Locations: 🇺🇸
Modern Research Associates, Dallas, Texas, United States
🇺🇸
Univ of Connecticut, Farmington, Connecticut, United States
🇺🇸
Dermatologic Surgery Specialists, PC, Macon, Georgia, United States

and more 225 locations

A Study of Insulin Glargine (LY2963016) in Healthy Chinese Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Insulin Glargine
Drug: Lantus

First Posted Date: 2018-06-13

Last Posted Date: 2020-11-24

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 58

Registration Number: NCT03555305

Locations: 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China

An Expanded Access Program for AM0010 (Pegilodecakin)

Conditions: Ovarian Cancer
Pancreatic Carcinoma
Breast Cancer
Non-small Cell Lung Carcinoma
Solid Tumors
Melanoma
Prostate Cancer
Colorectal Carcinoma
Renal Cell Carcinoma

First Posted Date: 2018-06-13

Last Posted Date: 2020-03-02

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT03554434

A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants

Phase 1

Withdrawn

Conditions: Renal Insufficiency

Interventions: Drug: Lanabecestat
Drug: Iohexol

First Posted Date: 2018-06-04

Last Posted Date: 2018-06-28

Lead Sponsor: Eli Lilly and Company

Registration Number: NCT03545087

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Ctr., Orlando, Florida, United States

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

Phase 3

Completed

Conditions: Psoriasis

Interventions: Drug: Secukinumab
Drug: Mirikizumab
Drug: Placebo

First Posted Date: 2018-05-24

Last Posted Date: 2021-03-30

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1484

Registration Number: NCT03535194

Locations: 🇦🇺
Clinical Trials SA Pty Ltd, Adelaide, South Australia, Australia
🇺🇸
Dawes Fretzin Clinical Research, Indianapolis, Indiana, United States
🇺🇸
Dermatology Associates, Seattle, Washington, United States

and more 174 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy